Lpcn 1148 phase 2 study meets primary endpoint in patients with cirrhosis

Met primary endpoint: treatment with lpcn 1148 increased l3 skeletal muscle index (l3-smi) relative to placebo (p 1 in the lpcn 1148 treatment arm relative to placebo (p < 0.05) more patients on lpcn 1148 reported symptom improvement compared to placebo (p < 0.05) lpcn 1148 was well-tolerated, with ae rates and severities similar to placebo conference call and webcast today at 8:30am et salt lake city , july 27, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders by leveraging its proprietary platform to develop differentiated products, today announced positive topline results from a phase 2 clinical study of lpcn 1148. lpcn 1148 is an oral candidate under development for the clinical management of cirrhosis.
LPCN Ratings Summary
LPCN Quant Ranking